Tesamorelin

Tesamorelin is a synthetic peptide that stimulates the release of growth hormone by mimicking the body's natural Growth Hormone-Releasing Hormone (GHRH). It is FDA-approved for reducing excess abdominal fat in HIV-positive patients with lipodystrophy and is also being studied for its potential effects on body composition, metabolism, and healthy aging.

Tesamorelin is FDA-approved for use in HIV-associated lipodystrophy. Other uses remain investigational. This information is provided for educational purposes only and does not constitute medical advice.

What is Tesamorelin?

Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH 1-44) developed to stimulate the pituitary gland's natural production of growth hormone (GH). It is FDA-approved for reducing visceral adipose tissue (VAT) in HIV-positive adults with lipodystrophy and is also being researched for broader applications in fat loss, metabolism, cognitive function, and liver health.

Potential Benefits Shown in Studies

Increasing natural growth hormone production
Reducing deep belly fat (visceral adipose tissue)
Supporting lean muscle growth and recovery
Improving lipid (cholesterol) profiles
Enhancing metabolic health and insulin sensitivity
Supporting cognitive function and memory
Promoting healthy aging and body composition

Mechanisms of Action

Tesamorelin works by:

Binding to GHRH receptors in the pituitary gland
Stimulating pulsatile release of GH, mimicking natural secretion
Raising circulating IGF-1 levels, supporting tissue growth and metabolism
Promoting lipolysis (fat breakdown), especially in visceral fat deposits

Unlike exogenous GH, Tesamorelin preserves the body's feedback loops and reduces the risk of GH oversaturation.

Research Highlights

FDA-Approved for HIV-Associated Visceral Fat Reduction

Tesamorelin (Egrifta®) is FDA-approved for reducing visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy, with clinical trials demonstrating significant VAT loss and improvements in body composition, lipid profile, and insulin sensitivity.

Source: Metical Anti-Aging Evidence

Versatile Metabolic & Longevity Applications

Emerging research is exploring Tesamorelin’s effects beyond HIV lipodystrophy, including reducing hepatic steatosis and liver fibrosis in NAFLD, improving cognitive function, insulin resistance, and other aging-related metabolic markers.

Source: PeptidesWiki Clinical Trial Summary

Ongoing Research in Cognitive Aging & Nerve Repair

Current Phase II trials are evaluating Tesamorelin’s potential in improving cognitive function in aging HIV populations, and in enhancing motor and sensory recovery after peripheral nerve injuries.

Source: CenterWatch Clinical Trial Listing

Favorable Metabolic Biomarker Profiles

Tesamorelin has been shown to improve lipid metabolism—lowering triglycerides by ~15% and increasing HDL—while maintaining or even enhancing insulin sensitivity, and improving glucose homeostasis.

Source: Biology Insights Metabolic Overview